Recall T cell responses to bluetongue virus produce a narrowing of the T cell repertoire
José-Manuel Rojas, Teresa Rodríguez-Calvo, Noemí Sevilla

To cite this version:
José-Manuel Rojas, Teresa Rodríguez-Calvo, Noemí Sevilla. Recall T cell responses to bluetongue virus produce a narrowing of the T cell repertoire. Veterinary Research, BioMed Central, 2017, 48 (1), pp.38. <10.1186/s13567-017-0444-3>. <hal-01551055>

HAL Id: hal-01551055
https://hal.archives-ouvertes.fr/hal-01551055
Submitted on 29 Jun 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Recall T cell responses to bluetongue virus produce a narrowing of the T cell repertoire

José-Manuel Rojas1, Teresa Rodríguez-Calvo1,2 and Noemí Sevilla1*

Abstract

In most viral infections, recall T cell responses are critical for protection. The magnitude of these secondary responses can also affect the CD8 and CD4 epitope repertoire diversity. Bluetongue virus (BTV) infection in sheep elicits a T cell response that contributes to viremia control and could be relevant for cross-protection between BTV serotypes. Here, we characterized CD4+ and CD8+ T cell responses during primary and recall responses. During primary immune responses, both CD4+ and CD8+ T cell populations expanded by 14 days post-infection (dpi). CD4+ T cell populations showed a lower peak of expansion and prolonged contraction phase compared to CD8+ T cell populations. Recall responses to BTV challenge led to BTV-specific expansion and activation of CD8+ but not of CD4+ T cells. The evolution of the BTV-specific TCR repertoire was also characterized in response to VP7 peptide stimulation. Striking differences in repertoire development were noted over the time-course of infection. During primary responses, a broader repertoire was induced for MHC-I and MHC-II epitopes. However, during memory responses, a narrowed repertoire was activated towards a dominant motif in VP7 comprising amino acids 139–291. Monocytes were also examined, and expanded during acute infection resolution. In addition, pro-inflammatory cytokine levels increased after BTV inoculation and persisted throughout the experiment, indicative of a prolonged inflammatory state during BTV infections. These findings could have implications for vaccine design as the narrowing memory T cell repertoire induced after BTV re-infection could lead to the development of protective immunodominant TCR repertoires that differs between individual sheep.

Introduction

The role of memory T cells is to help protect the host during secondary antigen encounters. These secondary responses can reinforce the quantity and quality of the immune response against the challenging pathogen [1]. This is reflected by the increased frequency of antigen-specific T cells able to mount accelerated responses, with shorter antigenic stimulation leading to efficient and quicker antigen clearance. However, T cell exhaustion can also occur in the presence of saturated levels of antigen or even after repetitive natural or vaccination exposures.

In particular, an understanding of T cell recruitment/expansion process during the recall response may have significant implications for effective control strategies. Different mechanisms of memory recruitment have been postulated. A memory population in which highly effective clones predominate may occur as a stochastic expansion, more likely maintaining the T cell diversity, which was shown to be beneficial for virus control [2]. Alternatively, by deterministic selection, high quality clones in the memory population may be expanded by antigen-driven mechanisms [3], narrowing the T cell repertoire [4].

Bluetongue virus (BTV) is the prototype member of the genus Orbivirus within the Reoviridae family, transmitted by Culicoides midges [5]. BTV infects ruminants, causing an acute disease with high morbidity and mortality [6]. The BTV genome is composed of 10 segments...

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
of double-stranded RNA encoding 4 non-structural and 7 structural proteins that is enclosed by a complex capsid structure [7, 8]. There are at least 27 serotypes circulating based on the specific neutralizing antibodies raised against VP2 [9–11]. The immune response against BTV is characterized by the induction of humoral responses, neutralizing antibodies, and cellular immunity that contributes significantly to protection in vaccinated animals [12–15]. Virus-specific CD8+ cytotoxic T lymphocytes (CTL) are key components of the immune response, inducing cross-protection among different serotypes [16, 17]. In nature, high frequency of repeated BTV infections due to successive bites by biting midges may occur, meaning successive challenges with other BTV serotypes (heterologous virus) or with the same serotype (homologous virus).

Immune responses to viral infections are not mounted in immunological isolation, as the immune response to one virus may condition the host to elicit an altered immune response against a homologous or heterologous virus. Using successive challenge with BTV-8, we investigated the expansion of VP7-specific CD8+ and CD4+ T cells [18]. Furthermore, we studied the inflammatory response during recall responses. Here, we show that recall responses with BTV led to BTV-specific expansion and activation of CD8+ but not of CD4+ T cells. Interestingly, during primary responses, a broader repertoire of T cell epitopes was induced. However, during memory responses, a narrowed repertoire was activated towards a dominant epitope in VP7.

Materials and methods

Virus

A BTV-8 isolate (Belgium/06) from an infected calf in the 2006 Belgium outbreak was used in this study [19]. BTV-8 was expanded in baby hamster kidney (BHK) cells (ATCC CCL-10) and titered in semi-solid agar medium in Vero cells (ATCC CCL-81) as described [20]. BTV-8 inactivation with binary ethylenimine (BEI) was performed as described [21].

Animals and experimental design

Three-month-old BTV naive female Mallorquina sheep were kept in a disease-secure isolation facility (BSL3) at the Centro de Investigación en Salud Animal (CISA), in strict accordance with the recommendations in the guidelines of the Code for Methods and Welfare Considerations in Behavioural Research with Animals (Directive 86/609EC; RD1201/2005) and all efforts were made to minimize suffering. Experiments were approved by the Committee on the Ethics of Animal Experiments (CEEA) (Permit Number: 10/142792.9/12) of the Spanish Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA) and the “Comisión de ética estatal de bienestar animal” (Permit Numbers: CBS2012/06 and PROEX 228/14). An acclimatization period of 2 weeks was observed, during which the animals were monitored daily for general health status prior to the experiment.

Animals (n = 8) were inoculated subcutaneously with 1 × 10⁵ pfu BTV-8 three times at 28 day intervals. Two naive controls were inoculated with PBS at the same time points as the control group.

Peripheral blood mononuclear cell isolation

Venous blood from BTV-8 infected sheep was collected on days 0, 7, 14, 28, 35, 56, 63 and 70, and PBMC were isolated by standard centrifugation methods on Ficoll [18]. Flow cytometry studies were performed on freshly isolated PBMC. Remaining PBMC were frozen and stored in liquid nitrogen until use.

Peptides and antibodies

Peptides from BTV-8 VP7 protein (ACJ06230) were selected as described in [18] and synthesized by Altabiosciences (Birmingham, UK) (Table 1 corresponds to oligonucleotide sequences). All peptides were resuspended in DMSO and stored at −80 °C. The following directly conjugated antibodies were used in this study: anti-sheep CD4 (44.38); anti-sheep CD8 (38.65); anti-human (cross-reactive with sheep) CD14 (TÜK4) (all from Biorad); anti-BTV-VP7 (CF-J-BTV-MAB-10ML).

Flow cytometry

Surface flow cytometry stainings were performed using staining buffer (PBS + 2% FBS + 0.05% sodium azide). PBMC were washed twice, stained with antibodies for 20 min on ice, and finally washed twice in staining buffer. For BTV-VP7 intracellular staining, PBMC were fixed in 4% paraformaldehyde for 10 min, permeabilized and washed 3 times in staining buffer containing 0.2% saponin and incubated for 30 min on ice with antibody diluted in staining buffer supplemented with 0.2% saponin. For all stainings appropriate isotype and fluorescence minus one controls were included. Acquisitions were performed on a BD FACScalibur flow cytometer and analysis using FlowJo software (Tree Star Inc, USA).

### Table 1 Primer sequences for real-time RT-PCR

| Gene   | Forward (5′–3′) | Reverse (5′–3′) |
|--------|----------------|----------------|
| IL-6   | CCCCCAGGAACCCAGCTATG | GGAGACAGCGAGTGGACTGAA |
| IL-15  | CGAAACATGTCCTTCGGTGATG | TCTCTGTCCTGGGAGTTTGCAT |
| IL-12  | CGTGATGGAAGCTGTGCAC | CTTTCCTGGACCTGAACAC |
| CXCL10 | GCTCATCACCCTGAGCTGTT | AGCTGGCAGTAGCAAGGCTA |
RNA isolation, reverse transcription and quantitative real-time PCR to determine viral load

RNA from total blood was obtained using Trizol Reagent Solution (Thermo Fisher Scientific) and following the manufacturer’s protocol. Viral RNA loads were determined by amplification of segment 5 as described [12, 22] using the QIAGEN OneStep RT-PCR kit (QIAGEN) or the Ambion AgPath-ID One-Step RT-PCR (Thermo Fisher Scientific).

Expression of immune genes by real time PCR

Total RNA was extracted from PBMC isolated at different times post-infection using Trizol Reagent Solution (Thermo Fisher Scientific). Isolated RNA was treated with DNase I (BioLabs New England) according to the manufacturer’s protocol. 1 μg of RNA was used to obtain cDNA using the SuperScript™II reverse Transcriptase (Thermo Fisher Scientific) and oligo (dT)12–18 (0.5 μg/mL). To evaluate the levels of transcription of IL-12, IL-6, CXCL10 and IL-1β, real time was performed in a LightCycler 480 System instrument (Roche) using SYBR Green PCR core Reagents (Applied Biosystems) and specific primers (Table 1). Each sample was measured under the following conditions: 10 min at 95 °C followed by 45 amplification cycles (15 s at 95 °C and 1 min at 60 °C). The expression of individual genes was normalized to relative expression of ovine GPDH gene and the expression levels were calculated using $2^{-\Delta Ct}$ method, where ΔCt is determined by subtracting the GPDH value from the target Ct. A melting curve for each PCR fluorescence reading, every degree between 60 and 95 °C, was determined to ensure that only a single product had been amplified.

ELISA for sheep IFN-γ

PBMC (2 × 10⁵ per well) were stimulated for 24 h in U-bottom 96 well plates with BEI-BTV-8 (equivalent to 1 × 10⁵ pfu prior to inactivation), concanavalin-A (2.5 μg/mL) as the positive control, VP7 peptide (10 μg/mL), or an equivalent volume of DMSO as the negative control. IFN-γ production in culture supernatants was then tested using a commercially available IFN-γ ELISA kit (Mabtech, Sweden). The ELISA detection limit was 20 pg/mL. Data were normalized to 1 × 10⁶ PBMC.

Statistical analysis

Statistical analysis was performed using Prism 5.0 software (Graphpad Software Inc, USA). Levels of significance were *p < 0.05; **p < 0.01; ***p < 0.001.

Results

Clinical responses

In order to evaluate and compare the expansion of the immune response after primary and secondary BTV infections, one in vivo experiment with 10 animals was done, in which 8 sheep were inoculated sc with BTV-8 three times at 28-day intervals (see “Materials and methods”). All animals inoculated with BTV-8 developed clinical signs and fever (> 40 °C during four successive days) at days 5–8 post-infection (Figure 1). The first sign of the disease was a slight to moderate increase in respiratory rate, accompanied by inflammation of the oral mucosa. After day 9, temperature declined to normal levels and disease signs were detectable up to day 15, achieving full recovery afterwards. BTV-8 inoculation at day 28 and 56 did not increase rectal temperature nor produce clinical signs, suggesting that an efficient BTV-specific immune response had been elicited in BTV-infected sheep. Control PBS-inoculated sheep did not show any clinical signs or fever during the experiment.

Expansion of PBMC after challenge with BTV in primary and secondary responses

To evaluate the immune response after primary and secondary BTV infections, and according to the scheme indicated above, total PBMC were isolated from peripheral blood and quantified at different times post-inoculation. During primary response, a significant decrease in the number of PBMC was detected at day 7 post-infection (D7pi) returning to basal levels by D14pi (Figure 2A). Twenty-eight days later, sheep were inoculated with the same amount of BTV-8 sc (secondary BTV infection) and the number of PBMC was determined. In contrast to the primary infection, PBMC levels did not decrease 7 days after the second infection (D35pi) and significantly increased 14 days after this second infection (D42pi), followed by a contraction period. Similar results were obtained after the third challenge. Because BTV may infect lymphocytes causing cell death [23], we next asked whether BTV infection of PBMC would result

![Figure 1 Temperature measurements after primary and recall BTV-8 infections in sheep.](image-url)
Figure 2  Expansion of PBMC and viral load during acute and recall BTV infection. Sheep were inoculated with BTV-8 three times at 28-day intervals (see "Materials and methods" section) and bled at different times post-inoculation. A Average count of PBMC relative to pre-BTV infection at different days post-inoculation. The arrow indicates the inoculation day. * \( p < 0.05; \) Mann-Whitney test (timepoint vs inoculation time). B Number of PBMC/mL of blood that were positive for VP7 by flow cytometry staining at different days post-BTV infection. Arrows indicate inoculation days. * \( p < 0.05; \) ** \( p < 0.01; \) Mann-Whitney test (timepoint vs day 0). C Whole blood was collected at different days post-BTV infection. Total RNA was extracted and RT-qPCR for BTV segment 5 was performed as indicated in the "Materials and methods". The results are expressed as Ct. The cut-off is indicated with a dotted line (Ct = 40 according to [22]).
in PBMC depletion after primary infection. PBMC were labeled with a specific monoclonal antibody against the VP7 protein and directly coupled to a fluorochrome probe. A significant amount of PBMC were positive for VP7 protein by flow cytometry analysis (average of $1.51 \times 10^5 \pm 0.2$ PBMCs/mL from 8 sheep infected with BTV-8) by D7pi (Figure 2B), suggesting that the D7pi decrease in PBMC numbers might be due to BTV-induced cell death. The number of VP7 positive cells did not increase after secondary infection but it was maintained until at least D45pi. After the third infection, a significant increase of VP7 positive PBMC was observed, suggesting that a brief round of BTV infection occurred shortly after inoculation (D3pi). This contrasts with primary infection where the peak of VP7 positive cells was obtained at D7pi. To assess virus replication, blood samples for each sheep were examined for viral genome by RT-qPCR. A peak in viremia was found at D7pi (average Ct value of 26.82 ± 3) followed by a slow reduction in circulating virus. Importantly, the infection was not completely cleared by the end of the experiment (average Ct value 33.1 ± 1.4 at D63pi) (Figure 2C). New viremia peaks were nonetheless never detected after secondary or tertiary challenge. Taken together these data suggest that during secondary BTV infections PBMC expanded but BTV infection was not completely controlled.

Re-exposure to virus controls the magnitude of the CD4 and CD8 T cell responses

Given that total PBMC numbers expanded 14 days after acute (D14pi vs D7pi) and secondary infections with BTV (D42pi vs D28pi and D56pi vs D70pi), we examined whether an increase in CD4+ or CD8+ T cell populations could explain this expansion. CD4+ T cell numbers started to increase significantly at D7pi, maintaining this trend up to D28pi (Figure 3A). Surprisingly, the population of CD4+ T cells slightly declined 7 days after the second infection (D35pi) but increased 15 days later (D42pi). After the third BTV challenge, the CD4+ T cell population did not show any significant changes in numbers although at D15 post-third infection (D70pi) CD4+ T cell numbers slightly increased. In general, CD8+ T cell responses peak at about 1 week post-infection in most viral infections, and soon thereafter, virus-specific T cells eliminate the virus [24, 25]. Interestingly, CD8+ T cell responses peaked at D14 post-BTV challenge both in acute (D14pi) and secondary responses (D42pi and D70pi) (Figure 3B). CD8+ T cells thus proliferated in response to the virus, independently of primary or secondary infections. The decrease in CD8+ T cell numbers following D15pi expansion led to a subsequent significant decrease in the CD8:CD4 T cell ratio (Figure 3C). Although repeated infections slightly increased CD8+ T cell numbers (D42pi and D70pi), CD4:CD8 T cell ratios were unchanged as CD4+ T cell numbers slightly increased concomitantly. This unchanged CD8:CD4 T cell ratio indicated that CD8+ T cells did not significantly proliferate after antigen re-exposure. Thus, our findings indicate that levels of central CD8+ memory T cells did not stabilize after primary infection, suggesting that in the absence of further infections the memory level of CD8+ T cells would continually decline.

Characterization of T cell responses after primary and secondary infections

We next sought to analyze the BTV-specific CD4+ and CD8+ T cell responses. The global T cell responses were first evaluated to determine differences in the overall magnitude of the responses to primary and secondary BTV infections. To this end, PBMC from BTV-infected sheep were isolated at different times post-infection, stimulated in vitro with inactivated-BTV-8, and IFN-γ production was evaluated by ELISA. A significant production of IFN-γ was found at D15pi after primary infection (D0) (Figure 4). Recall infections also induced significant IFN-γ responses 7 and 15 days after the second or third challenge (D35pi, D63pi and D70pi). In addition, the amplitude of these T cell responses increased over time, suggesting that there was a prolonged activation of T cell responses during the observed period, probably due to inefficient virus clearance that might continuously activate CD8+ T cells responses.

T cell recognition of infected cells is accomplished by the interaction of clonally distributed TCR on effector cells with the complex of viral peptide/MHC class I-II on infected cells [26, 27]. The specificity of T cells for a particular MHC/peptide combination determines, at least in part, the TCR repertoires within an antigen-specific population. In order to determine the spectrum of the TCR repertoire against VP7 during primary and recall responses, PBMC from BTV-infected sheep were stimulated in vitro with peptides that comprise the main T cell epitopes in VP7 protein (Figure 5A) [18], and the production of IFN-γ was measured by ELISA. During acute infection, most T cells synthesized IFN-γ in response to most of the epitopes (D7pi and D14pi) (Figure 5B), showing a broad distribution of TCR diversity. This was also observed after secondary response, in which T cell responses to all the epitopes were detected. However, by D70pi, after the third BTV challenge, a T cell response bias towards 3 MHC-I epitopes [VP(175), VP(245) and VP(283)] and 2 MHC-II epitope [VP(139) and VP(181)] became apparent. All these epitopes were grouped in a cluster of 100 amino acids of VP7, indicating a restriction in the TCR diversity that responds to BTV after repeated infections and thereby a narrowing of the TCR repertoire during memory responses.
Figure 3  CD4\(^+\) and CD8\(^+\) T cell expansion during acute and recall BTV infection. PBMC were obtained at the indicated time points after primary, secondary or tertiary BTV infection (indicated by an arrow) and staining for CD4 and CD8-T cell was done by flow cytometry (see "Materials and methods"). **A** Number of CD4\(^+\)-T cells over time in PBMC of individual sheep. *p < 0.05; Mann-Whitney test (timepoints vs inoculation time). **B** Number of CD8\(^+\)-T cells in PBMC over time of individual sheep. *p < 0.05; Mann-Whitney test (time points vs inoculation time). **C** Kinetics of specific CD8:CD4 T-cell ratio. The number of CD8\(^+\) T cells was divided by the number of CD4\(^+\) T-cells during the time course of infection. **p < 0.01; Mann-Whitney test (day 14 vs all timepoints).
Persistent inflammation during acute and secondary responses

Upon virus infection, monocytes play a role in initiating the adaptive immune response, and affect Th1/Th2 polarization by producing proinflammatory and immune-modulatory cytokines [28]. Therefore, we studied the magnitude of the monocyte response during primary and secondary BTV responses by flow cytometry in PBMC from sheep infected with BTV. Analysis of CD14-expressing cells (Figure 6A) revealed a steady increase in CD14+ monocytes during infection. This increase was transient and started to decline by D28pi, right after the second challenge with BTV. By day 15 after the second BTV challenge (D42pi), CD14+ cell numbers increased followed by a progressive decline by D56pi. After the third BTV challenge (D56pi), the population of CD14-expressing cells increased until the experiment ended. To study the cytokine/chemokine response during BTV infection, we determined the amount of mRNA expressed by PBMC from BTV-infected sheep at different time points by RT-qPCR. IL-6 and IL-1β were chosen as representative pro-inflammatory cytokines [29, 30]. IL-6 transcription was significantly up-regulated during primary infection, starting at D7pi (Figure 6B) and during the course of the second BTV challenge. However, after D56pi, IL-6 mRNA transcripts declined to levels similar to prior BTV infection. In contrast, IL-1β mRNA levels showed an opposite transcription pattern to IL-6. IL-1β mRNA was not up-regulated until the third challenge, by D56pi (Figure 6B). In addition to these pro-inflammatory cytokines, transcript levels of IL-12, a classical Th1 cytokine [31] and CXCL10, a chemokine that mediates leukocyte trafficking and activates Th1 responses (reviewed in [32]) were evaluated. Both cytokines showed a significant up-regulation of transcription during infection until D56pi (Figure 6B). Thus, IL-6, IL-12 and CXCL10 were significantly up-regulated after primary and secondary responses while IL-1β was up-regulated only after D56pi, suggesting that an active inflammatory response was induced during primary and secondary BTV infection that did not involve IL-1β.

**Discussion**

In this report we analyzed the T cell immune response elicited in sheep after repetitive infections with BTV-8, mimicking several peaks of vector activity during the course of the year [33]. Our results show that although an expansion of PBMC occurs after serial BTV inoculations, the infection is not completely controlled, resulting in detectable BTV RNA by RT-qPCR. Similarly, in BTV-8-immunized calves BTV1/15 replication still occurred after heterologous challenge [34]. In our study, the characterization of the expansion of CD4+ and CD8+ T cell responses during primary and secondary responses demonstrated a burst in size of the CD8+ but not the CD4+ population 15 days after each challenge. Moreover, IFN-γ production was also detected 15 days after primary and secondary challenge, although the TCR repertoires present within primary responses and secondary recall responses were different. These findings indicate that during BTV reinfections there is a bias of T cell responses towards a more specialized T cell pool that results in the narrowing of the T cell repertoire.

The study of the fluctuation of the PBMC population during primary and secondary BTV infections revealed that after primary infection the number of PBMC declined significantly, whereas those numbers increased after secondary and tertiary infections. The early decline of PBMC during primary BTV infection support previous results where a high proportion of apoptosis in PBMC was observed during the peak of viremia [23]. In fact, our data show that a high number of PBMC are BTV-infected, which presumably triggers apoptosis in these cells [35]. When the virus is no longer detected in PBMC, the population expands after secondary and tertiary recall responses, supporting the hypothesis that BTV might induce PBMC apoptosis at early stages during infection. This becomes especially relevant during acute infections in which a potent T cell response is needed to mediate viral clearance. PBMC infection leading to cell death could thus dampen the immune response and promote BTV survival.

We have outlined differences between CD8+ and CD4+ T cell expansion after primary and secondary
responses. CD4⁺ T cells, which help to promote B cell antibody production and are required for the generation of cytotoxic and memory CD8⁺ T cells (reviewed in [36, 37]), did not significantly increase in numbers during the time course studied here, although they displayed a trend towards an increase. This lack of significant CD4⁺ T cell expansion may be the consequence of a slowly controlled infection, or even a lack of control due to serial infections. This possible scenario in which high viral loads impair virus-specific CD4⁺ T cell responses has been reported for other viral infections [38, 39].

For BTV, the viral load at the peak of primary infection (D7pi) is very high (Ct values < 25), and is kept low or medium (Ct value > 30–40) after recall responses and until the end of the experiment. Thus, we speculate that although the viral load may not be high enough to completely impair virus-specific CD4⁺ T cell responses, our data suggest that this low/medium viral load (antigen load) is affecting the expansion of CD4⁺ T cells. The typical contraction phase of CD4⁺ T responses after acute viral infection was not detected in our experiment, in which the CD8:CD4 T cell ratio was stabilized after primary infection and never decreased. Nevertheless, it is also plausible that these data reflect a rapid contraction phase combined with ongoing CD4⁺ T cell recruitment to lymph nodes. By contrast, the kinetic of CD8⁺ T cells displays an expansion by D15pi followed by a contraction phase and expansions after secondary infections. Our results support previous work in which the rate of proliferation was similar for naïve and memory CD8⁺ T cells [3, 40]. In addition, our data show that CD8⁺ T cell responses in acute infection reached their highest responses by D15pi, which indicates that optimal CD8⁺ T cell expansion could require the presence of antigen
for at least 12 days following BTV infection. For memory response upon challenge, CD8\(^+\) T cells initiate division and IFN-\(\gamma\) production with a significantly reduced duration of antigen exposure when compared to naïve T cells [41]. By D7 post-secondary infection CD8\(^+\) T cells already expand and produce IFN-\(\gamma\). Our data thus indicate a clear activation of CD8\(^+\) T cells upon secondary challenge with BTV, due to the activation of memory CD8\(^+\) T cells that may, ideally, cross-react [21] between previously and newly encountered BTV strains.
In many viral infections, bulk T cell responses correlate weakly with the control of virus replication, whereas T cell responses to subdominant epitopes can play an important role in limiting infection [42, 43]. Moreover, antigen dose can also modify the immunodominance hierarchy of T cell epitopes [44], and thus repeated infections (and thereby increased antigen exposure) could alter the antiviral T cell response. We have characterized the evolution of the TCR repertoires specific for the VP7 protein from acute to secondary homologous BTV infection. Acute and secondary infection with BTV induces very broad repertoires in which T cell responses target a relatively high number of epitopes in VP7 (Figure 4). By contrast, after a third BTV challenge, a profound narrowing of the TCR repertoire was observed, in which 3 MHC-I and 2 MHC-II epitopes were detected. The possibility of clonotyping and/or determining the TCRβ chain usage [45] of the narrowing anti-BTV T cell repertoire could prove useful to further understand T cell responses to BTV infections in future work. In conventional vaccine design, the most immunogenic epitopes have been chosen to generate a high number of T cells directed against these dominant epitopes, and thus the T cell repertoire tends to be focused on a few epitopes [42, 46]. However, our data show that a broader T cell repertoire is initially raised to fight the incoming virus but that after recurrent infection the virus is now more likely to select and drive the activation of a more focused T cell repertoire. These findings raise the interesting possibility that a broad anti-BTV T cell repertoire may induce a faster clearance of BTV infection than a narrowly focused T cell response.

Recombinant vaccines expressing BTV subunits could therefore prove useful to trigger a broad T cell repertoire against BTV. For instance, vaccination with a recombinant adenovirus vaccine expressing VP7 partially protected sheep from a virulent challenge [12]. Adenoviral vectors can induce CD4+ T cell mucosal immunity and strong memory CD8+ T cell responses to the transgene they express [47–50]. The recombinant vaccine expressing VP7 induced a CD4+ T cell response and a robust CD8+ T cell response which was likely responsible for the control of BTV after virulent challenge. These recombinant vaccine platforms that express BTV subunits and adequately activate T cells could therefore be ideal to broaden and induce long-term memory T cell responses.

The study of the inflammatory response after sequential BTV infections revealed interesting data. IL-6, a cytokine mainly produced by activated monocytes, with pleiotropic action affecting the functions of a variety of immune cells (reviewed in [29]), is up-regulated during primary and secondary responses, and declines after the third infection. IL-6 synthesis is triggered by pathogen-recognition receptor engagement [29], and probably induced by BTV dsRNA recognition by the cell. IL-6 induces the production of the cytokine VEGF (vascular endothelial growth factor), among others, leading to angiogenesis and increased vascular permeability [51]. BTV infection is characterized by increased vascular permeability and endothelial cell dysfunction, leading to hemorrhages and edema [52]. Therefore, the high levels of IL-6 found during primary and secondary BTV infections might contribute to BTV-induced vasoactive disease. IL-6 is nonetheless also important for the development of adaptive immunity and its upregulation could help combat the infection. IL-6 promotes T follicular cell help and thus favors antibody production [53]. Moreover, it has been linked to the differentiation of activated B cells into antibody-producing plasma cells and the differentiation of CD8+ T cells into cytotoxic T lymphocytes [29].

Intriguingly, BTV-8 infection only induced IL-1β expression after the third viral challenge. Our results are in accordance with others, which have reported that BTV-1 primary infection triggered IL-1β expression but BTV-8 inoculation failed to induce the production of this cytokine [54]. The pro-inflammatory cytokine IL-1β is produced mostly by monocytes, macrophages and dendritic cells after pattern recognition receptor engagement and inflammasome activation [55, 56]. IL-1β promotes the recruitment of inflammatory and immune competent cells to the inflamed tissue. It is also essential for T cell-dependent antibody production [57], a pathway that BTV disrupts during infection [58]. Blockade of IL-1β activation could thus facilitate BTV survival. The increase in IL-6 detected during the first and second challenge could also contribute to impaired IL-1β activity. IL-6 triggers the production of the IL-1 receptor antagonist IL-1Ra that blocks IL-1β and IL-1α signaling [56, 59]. IL-1Ra induction by IL-6 can protect mice from autoimmune disease [59]. Whether the high IL-6 levels detected after BTV-8 infection impairs IL-1β activity will nonetheless require further investigation.

IL-12 is also a pro-inflammatory cytokine produced by B cells, macrophages and dendritic cells in response to infection (reviewed in [31, 60]). IL-12 induces IFN-γ production by T cells and drives Th1 differentiation. CXCL10 is a chemoattractant for monocytes, T cells and NK cells towards inflamed areas (review in [32]). Our data were consistent with a positive feedback loop between IFN-γ-producing Th1 cells that induce CXCL10 production on resident cells, which in turn enables CXCL10 to attract and recruit more Th1 cells.

In conclusion, BTV-8 infection induces an inflammatory response in the host characterized by increased IL-6, IL-12 and CXCL10 levels, but IL-1β levels only increased after the third infection. Our data indicate that BTV-8
infection induces a memory T cell response to subsequent homologous BTV challenges. BTV-8 re-infection also produced a narrowing of the T cell repertoire to VP7. This narrowing T cell repertoire that responds better and faster to homologous BTV challenge is, however, not sufficient to eradicate viral load. The induction and maintenance of a diverse anti-BTV T cell repertoire may therefore be more beneficial for BTV control. These findings could have implications for the design of serotype-cross-reactive BTV vaccines.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JMR carried out most of the experiments described in the manuscript and contributed to writing the article; TR carried out some of the experiments; NS, conceived the study, its design, coordination and wrote the article. All authors read and approved the final manuscript.

Acknowledgements
This work was funded by Grants AGL2012-33289 and AGL2015-62490-R from the Spanish Ministry of Economy and Competitiveness and S2013/进出-2906-PLATESA from Comunidad de Madrid and the European Union (European Regional development’s Funds, FEADER).

Author details
1 Centro de Investigación en Sanidad Animal (CISA-INIA), Instituto Nacional de Investigación Agraria y Alimentaria, Ctra Algete a El Casar km 8, Valdeolmos, 28130 Madrid, Spain. 2 Present Address: Institute of Diabetes Research, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg, Germany.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 18 March 2017   Accepted: 26 June 2017  Published online: 29 June 2017

References
1. Ahmed R, Gray D (1996) Immunological memory and protective immunity: understanding their relation. Science 272:54–60
2. Cukalac T, Chadderton J, Handel A, Doherty PC, Turner SJ, Thomas PG, La Gruta NL (2014) Reproducible selection of high avidity CD8+ T-cell clones following secondary acute virus infection. PLoS Natl Acad Sci U S A 111:1485–1490
3. Blair DA, Turner DL, Bose TO, Pham QM, Bouchard KR, Williams KJ, McAleer JP, Cauley LS, Vella AT, Lefrancois L (2011) Duration of antigen availability influences the expansion and memory differentiation of T cells. J Immunol 187:2310–2321
4. Cornberg M, Chen AT, Wilkinson LA, Brehm MA, Kim SK, Calcagno C, Gersh H, Puzeone R, Celada F, Welsh RM et al (2006) Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest 116:1443–1456
5. Mellon PS, Baylis M, Mertens PP (2009) Bluetongue. Academic Press, London
6. Schwartz-Cornil I, Mertens PP, Contreras V, Hemati B, Pascale F, Breda E, Mellon PS, Maciachlan NJ, Zientara S (2008) Bluetongue virus: virology, pathogenesis and immunity. Vet Res 39:46
7. Roy P (2005) Bluetongue virus proteins and particles and their role in virus entry, assembly, and release. Adv Virus Res 64:69–123
8. Ratnini M, Caporale M, Golder M, Franzoni G, Allam K, Nunes SF, Armez­zani A, Bayoumy A, Rixon F, Shaw A et al (2011) Identification and characterization of a novel non-structural protein of bluetongue virus. PLoS Pathog 7 e1002477
9. Maan S, Maan NS, Belagana­hil­lanh MK, Potgieter AC, Kumar V, Batra K, Wright JM, Kirkland PD, Mertens PP (2016) Development and evaluation of real time RT-PCR assays for detection and typing of bluetongue virus. PLoS One 11 e0163014
10. Maan S, Maan NS, Belagana­hil­lanh MK, Rao PP, Singh KP, Hemadri D, Putty K, Kumar A, Batra K, Krish­na­y­othi­yi et al (2015) Full-genome sequencing as a basis for molecular epidemiology studies of bluetongue virus in India. PLoS One 10 e0131257
11. Zientara S, Sanchez-Vizcaino JM (2013) Control of bluetongue in Europe. Vet Microbiol 165:33–37
12. Martin V, Pascual E, Avia M, Peña L, Valcarcel F, Sevilla N (2015) Protective efficacy in sheep of adenovirus-vectored vaccines against bluetongue virus is associated with specific T cell responses. PLoS One 10 e0143273
13. Stott JL, Osbun BI, Barber TL (1979) The current status of research on an experimental inactivated bluetongue virus vaccine. Proc Annu Meet U S Anim Health Assoc 83:55–62
14. Stott JL, Barber TL, Osbun BI (1985) Immunologic response of sheep to inactivated and virulent bluetongue virus. Am J Vet Res 46:1043–1049
15. Bouet-Cararo C, Contreras V, Caruso A, Top S, Slezec­howski M, Bergeron C, Viaronce D, Desprat A, Remly A, Guibert JM et al (2014) Expression of VP7, a bluetongue virus group specific antigen by viral vectors: analysis of the induced immune response and evaluation of protective potential in sheep. PLoS One 9 e111605
16. Takamatsu H, Jego MH (1989) Cultivation of bluetongue virus-specific ovine T cells and their cross-reactivity with different serotype viruses. Immunology 66:258–263
17. Andrew M, Whitley P, Janardhana V, Lobato Z, Gould A, Coupar B (1995) Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Vet Immunol Immunopathol 47:311–322
18. Rojas JM, Rodriguez-Calvo T, Peña L, Sevilla N (2011) T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep. Vaccine 29:6848–6858
19. Elbers AR, Backx A, Meroc E, Gerbert G, Staau­bach C, Hendrick­s G, van der Spek A, Mintiens K (2008) Field observations during the bluetongue serotype 8 epidemic in 2006. I. Detection of first outbreaks and clinical signs in sheep and cattle in Belgium, France and the Netherlands. Prev Vet Med 78:21–30
20. Calvo-Pillina E, Rodriguez-Calvo T, Anguita J, Sevilla N, Ortego J (2009) Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS One 4 e5171
21. Rojas JM, Peña L, Martin V, Sevilla N (2014) Ovine and murine T cell epitopes from the non-structural protein 1 (NS1) of bluetongue virus serotype 8 (BTV-8) are shared among viral serotypes. Vet Res 45:30
22. Toussaint JF, Sailleau C, Breard E, Zientara S, De Clercq K (2007) Blueto­ngue virus. Vet Res 187:2310–2321
23. Umeshappa CS, Singh KP, Nanjundappa RH, Pandey AB (2010) Apoptosis and immuno-suppression in sheep infected with bluetongue virus serotype 23. Vet Microbiol 144:310–318
24. Davenport MP, Price DA, McMichael AJ (2007) The T cell repertoire in infection and vaccination: implications for control of persistent viruses. Curr Opin Immunol 19:294–300
25. Stipp SR, Irignaz A, Wan F, Vedder D (2016) Timing of CD8 T cell effector responses in viral infections. R Soc Open Sci 3:150661
26. Zientara S, Sanchez-Vizcaino JM (2013) Control of bluetongue in Europe. Vet Microbiol 165:33–37
27. Martin V, Pascual E, Avia M, Peña L, Valcarcel F, Sevilla N (2015) Protective efficacy in sheep of adenovirus-vectored vaccines against bluetongue virus is associated with specific T cell responses. PLoS One 10 e0143273
28. Stott JL, Osbun BL, Barber TL (1979) The current status of research on an experimental inactivated bluetongue virus vaccine. Proc Ann Meet U S Anim Health Assoc 83:55–62
29. Tanaka T, Narazaki M, Kishimoto T (2014) IL‑6 in inflammation, immunity, and immuno-suppression in sheep infected with bluetongue virus serotype 8 (BTV-8) are shared among viral serotypes. Vet Res 45:30
30. Keyel PA (2014) How is inflammation initiated? Individual influences of IL‑1, IL‑18 and HMGB1. Cytokine 69:136–145
32. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, Stiles JK (2011) CXCL10/P-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22:121–130

33. Bruggler K, Rubel F (2016) Bluetongue disease risk assessment based on observed and projected Culicoides obsoletus spp. vector densities. PLoS One 8:e60330

34. Martelline L, Dal Pozzo F, Sarradin P, Van Campe W, De Leeuw I, De Clercq K, Thys C, Thiry E, Saegeerman C (2016) Experimental bluetongue virus superinfection in calves previously immunized with bluetongue virus serotype 8. Vet Res 47:73

35. Barratt-Boyes SM, Rossitto PV, Stott JL, MacLachlan NJ (1992) Flow cytometric analysis of in vitro Cytotoxic T lymphocyte virus infection of bovine blood mononuclear cells. J Gen Virol 73:1953–1960

36. Sant AJ, McMichael A (2012) Revealing the role of CD4(+) T cells in viral immunity. J Exp Med 209:1391–1395

37. Swain SL, McKinstry KK, Strutt TM, Linde CH, Hewitt HS, Sango K, Feeney P (2011) Memory CD4+ T cell immunodominance during primary influenza infection due to differences in antigen presentation, T cell avidity, and precursor numbers. J Immunol 187:1647–1657

38. Fuller MJ, Zajac AJ (2003) Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol 170:477–486

39. Schulze Zuer Wiesch J, Ciffrerda D, Lweis-Ximenez L, Kasprovicz V, Nolan BE, Streec H, Anjea J, Reyor LL, Allen TM, Lohse AW et al (2012) Broadly directed virus-specific CD8(+) T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 209:61–75

40. Stock AT, Jones CM, Heath WR, Carbone FR (2011) Rapid recruitment and activation of CD8+ T cells after herpes simplex virus type 1 skin infection. Immunol Cell Biol 89:143–148

41. Lauvau G, Boutet M, Williams TM, Chin SS, Chorro L (2016) Memory CD8(+)-T cells: innate-like sensors and orchestrators of protection. Trends Immunol 37:375–385

42. Frahm N, Kiepelaa R, Adams S, Linde CH, Hewitt HS, Sango K, Fenney ME, Addo MM, Lichterfeld M, Lahaye MP et al (2006) Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7:173–178

43. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG (1998) Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 187:1647–1657

44. Luciani F, Sanders MT, Oveisii S, Pang KC, Chen W (2013) Increasing viral dose causes a reversal in CD8+ T cell immunodominance during primary influenza infection due to differences in antigen presentation, T cell avidity, and precursor numbers. J Immunol 190:36–47

45. Lythe G, Callard RE, Hoare RL, Molina-Paris C (2016) How many TCR clonotypes does a body maintain? J Theor Biol 389:214–224

46. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB et al (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3:205–211

47. Benlahrech A, Harris J, Meiser A, Papagatsias T, Horning J, Hayes P, Lieber A, Athanasopoulos T, Bachy V, Cosgrove E et al (2009) Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A 106:19940–19945

48. Holst PJ, Ørskov C, Thomsen AR, Christensen JP (2010) Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol 184:4431–4439

49. Zhou D, Wu TL, Emmer KL, Kurupati R, Tuyishime S, Li Y, Giles-Davis W, Zhou X, Xiang Z, Liu Q et al (2013) Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus. Mol Ther 21:696–706

50. Suleman M, Galea S, Gavard F, Merillon N, Klonkowsi B, Tartour E, Richard J (2011) Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8βα dendritic cell subset. Vaccine 29:5892–5903

51. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:1521–1529

52. Howerton EW (2015) Cytokine release and endothelial dysfunction: a perfect storm in orbivirus pathogenesis. Vet Ital 51:275–281

53. Ma CS, Deenick EK, Batten M, Tangye SG (2012) The origins, function, and regulation of T follicular helper cells. J Exp Med 209:1241–1253

54. Sánchez-Cordón PJ, Pérez de Diego AC, Gómez-Villamandos JC, Sánchez-Vizcaíno JM, Pleguezuelos FJ, Garfia B, del Carmen P, Pedroza M (2015) Comparative analysis of cellular immune responses and cytokine levels in sheep experimentally infected with bluetongue virus serotype 1 and 8. Vet Microbiol 177:95–105

55. Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13:397–411

56. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550

57. Nakae S, Asano M, Horai R, Ikawura Y (2001) Interleukin-1 alpha, but not interleukin-1 alpha, is required for T-cell-dependent antibody production. Immunology 104:402–409

58. Meli E, Caporale M, Rocchi M, Martin V, Gaminio V, di Provdio A, Marzucchini G, Entrican G, Sevilla N, Palmarini M (2016) Follicular dendritic cell disruption as a novel mechanism of virus-induced immunosuppression. Proc Natl Acad Sci U S A 113:E6238–E6247

59. Samavedam UK, Kales K, Scheller J, Sadeghi H, Gupta Y, Jonkman MF, Schmidt E, Westermann J, Zilkens D, Rose-John S et al (2013) Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. J Autoimmun 40:74–85

60. Ma X, Trinchieri G (2001) Regulation of interleukin-6 receptor gene expression by the CD8α+ dendritic cell subset. Vaccine 18:4025–4034

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide efficient single-system submission
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit